The startup develops cannabinoid-based pharmaceuticals aimed at obtaining FDA approval for treating chronic pain and neurological disorders. By focusing on large, poorly managed conditions, the company provides patients with access to targeted cannabinoid therapies that address significant gaps in current treatment options.
Funding
$2.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Migraine and other neurological disorders represent a significant unmet medical need, with current treatments often proving inadequate or poorly tolerated by a large patient population. Existing therapies may not fully address the underlying biological mechanisms of these conditions, leaving many individuals without effective relief.
Solution
Delphian Therapeutics is developing cannabinoid-based pharmaceuticals targeting the endocannabinoid system to treat pain and neurological disorders, with an initial focus on migraine. By leveraging the science of natural cannabinoids, the company aims to create optimized medicines suitable for FDA and EMA approval. Their approach seeks to provide patients with targeted therapies that offer improved efficacy and safety profiles compared to existing options, addressing critical gaps in current treatment paradigms.
Target Audience
The primary target audience includes individuals suffering from migraines and other poorly managed pain and neurological disorders, as well as healthcare providers seeking alternative treatment options.
Features
- Optimized combinations of CBD and THC for targeted therapeutic effects
- Focus on obtaining FDA and EMA approval for cannabinoid-based medicines
- Development of S1-221, a lead candidate for migraine treatment, advancing to Phase 1 clinical trials
- Leveraging partnerships with top migraine research labs in the U.S. and Europe
- Strict compliance with national and international laws and regulations for pharmaceutical product development